Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 73

Sort by

Sort Order Select

Journal Articles

A phase 2 trial of abbreviated fixed-duration (Default 4 Cycles) linvoseltamab immuno-consolidation to deepen responses post newly diagnosed multiple myeloma combination therapy for minimal residual disease positivity (the IMMUNOPLANT Study)

Blood (2025) 146 (Supplement 1): 248.

https://doi.org/10.1182/blood-2025-248

Published: 2025

Journal Articles

A Phase 2 trial of AI-BEL (AZT/Interferon-α plus Belinostat) for HTLV-1 related adult T-cell leukemia-lymphoma: Final safety and efficacy Results

Georgios Pongas, Isildinha Reis, Ngoc Toomey, Catalina Amador, Yi Zhou, Erik Guillen, Gregoire Lauvau, B. Hilda Ye, Jennifer Chapman, Juan Carlos Ramos

Blood (2025) 146 (Supplement 1): 563.

https://doi.org/10.1182/blood-2025-563

Published: 2025

Journal Articles

First-in-class small molecule calmodulin pathway modulators attenuate excess p53 activity and correct erythropoietic defects in models of diamond-blackfan anemia (DBA)

Avik Choudhuri, Heather Corry, Brian Lucas, Gary Luehr, David Matson, Billy Stuart, Sunita Patel-Hett, Lauren McGrath, Yi Zhou, Rajesh Gunage, Leonard Zon, Jeffrey Jacobs

Blood (2025) 146 (Supplement 1): 1441.

https://doi.org/10.1182/blood-2025-1441

Published: 2025

Journal Articles

Ponatinib alleviates CAR-T cell exhaustion and remodels the immune microenvironment: A promising combination strategy for relapsed/refractory b-ALL

Yi Zhou, Liwen Wang, Linzhi Xie, Qian Cheng, Jing Liu, Fangping Chen, Rong He, Xin Li

Blood (2025) 146 (Supplement 1): 2331.

https://doi.org/10.1182/blood-2025-2331

Published: 2025

Journal Articles

Individualized treatment risk stratification using histopathology-based genomics prediction in multiple myeloma: A multicenter Study in 1429 participants

Blood (2025) 146 (Supplement 1): 4008.

https://doi.org/10.1182/blood-2025-4008

Published: 2025

Journal Articles

Clinical translation of single cell measurable residual disease (scMRD) assay in real world Acute Myeloid Leukemia (AML) patients

Katarina Micin, Ellen Madarang, Tiffany Nong, Maurizio Affer, Kiana Robles, Felipe Novoa, Sion Williams, Ana Ayupe, Yi Zhou, Justin Watts, Justin Taylor

Blood (2025) 146 (Supplement 1): 280.

https://doi.org/10.1182/blood-2025-280

Published: 2025

Journal Articles

A cyno cross reactive CD3 VHH antibody enables engineering of a potent CD20-targeted t cell engager with enhanced safety

Blood (2025) 146 (Supplement 1): 3297.

https://doi.org/10.1182/blood-2025-3297

Published: 2025

Journal Articles

Targeting of the CD161 Inhibitory Receptor Enhances Bone Marrow-Resident Memory CD8 + T Cell-Mediated Immunity Against Multiple Myeloma

Liwen Wang, Linzhi Xie, Yi Zhou, Yan Yu, Shiming Tan, Qian Cheng, Rong He, Xin Li

Blood (2024) 144 (Supplement 1): 3291.

https://doi.org/10.1182/blood-2024-198964

Published: 2024

Journal Articles

Selinexor, Venetoclax, and Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (SELVEDge Study)

Blood (2024) 144 (Supplement 1): 7049.

https://doi.org/10.1182/blood-2024-193966

Published: 2024

Journal Articles

Reducing Time Toxicity for Anti-B-Cell Maturation Antigen (BCMA) Bispecific Treatment: Evidence from Pivotal Single-Arm Trial Data on Teclistamab, Elranatamab, and Linvoseltamab for Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)

Sikander Ailawadhi, Timothy J. Inocencio, Zheng-Yi Zhou, Michael K. Xu, Jack Eales, Michelle Little, Peter Quon, Qiufei Ma

Blood (2024) 144 (Supplement 1): 2271.

https://doi.org/10.1182/blood-2024-199182

Published: 2024

Journal Articles

Clinical Application of Single-Cell MRD By Genotype and Phenotype in AML

Katarina Micin, Tiffany Nong, Ellen Madarang, Kiana Robles, Maurizio Affer, Brittney Otero, Azad Gucwa, Felipe Novoa, Sion Williams, Ana Ayupe, Yi Zhou, Justin M. Watts, Justin Taylor

Blood (2024) 144 (Supplement 1): 4333.

https://doi.org/10.1182/blood-2024-207400

Published: 2024

Journal Articles

Transcription Factor Programming of Human iPSC-Derived Sinusoidal Vascular Endothelial Cells Enhances Co-Cultured Hematopoietic Stem and Progenitor Cell Transplantation

Tianxiao Han, Rajesh D. Gunage, Ran Jing, Olivia Stockard, Alexandra F. Corbin, Luca Hensch, Yang Tang, Kenny Chen, Song Yang, Yi Zhou, George Q. Daley, Thorsten M. Schlaeger, Leonard I. Zon

Blood (2024) 144 (Supplement 1): 820.

https://doi.org/10.1182/blood-2024-208453

Published: 2024

Journal Articles

Safety and Efficacy of AZT-Interferon-α with Belinostat (AI-BEL) for HTLV-1 Related Adult T-Cell Leukemia-Lymphoma

Georgios Pongas, Ngoc Toomey, Isildinha Reis, Jennifer R. Chapman-Fredricks, Yi Zhou, Erik Guillen, Eric Liu, Gregoire Lauvau, B. Hilda Ye, Juan Carlos Ramos

Blood (2024) 144 (Supplement 1): 1720.

https://doi.org/10.1182/blood-2024-209155

Published: 2024

Journal Articles

Characterization of Linvoseltamab's BCMA Binding Epitope and Efficacy Against BCMA Mutations in Relapsed/Refractory Multiple Myeloma

Ken Lee, Yi Zhou, Matthew Franklin, Erica Ullman, Aynur Hermann, Glenn S. Kroog, Anita Boyapati, Karen Rodriguez Lorenc, Eric Smith, John Lin, William Olson, Leonardo Andres Sirulnik, Kara Olson

Blood (2024) 144 (Supplement 1): 3265.

https://doi.org/10.1182/blood-2024-208776

Published: 2024

Journal Articles

Updated Results from a Matching-Adjusted Indirect Comparison of Efficacy Outcomes of Isatuximab Plus Carfilzomib and Dexamethasone Versus Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma

Joshua Richter, Peggy L Lin, Viviana Garcia-Horton, Patricia Guyot, Zheng-Yi Zhou, Mark Sievert

Blood (2023) 142 (Supplement 1): 6734.

https://doi.org/10.1182/blood-2023-188582

Published: 2023

Journal Articles

Does Detection of <20% Lymphoblasts in Patients with CML Herald Imminent Blast Crisis? a Study from BCR::ABL1 Pathology Group

Blood (2023) 142 (Supplement 1): 6364.

https://doi.org/10.1182/blood-2023-187020

Published: 2023

Journal Articles

Selinexor, Venetoclax, and Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (SELVEDge Study)

Blood (2023) 142 (Supplement 1): 6740.

https://doi.org/10.1182/blood-2023-180939

Published: 2023

Journal Articles

In Vivo Reprogramming of Adult Liver Sinusoidal Vascular Endothelial Cells into a Hematopoietic Stem and Progenitor Cell Niche

Tianxiao Han, Rajesh D. Gunage, Ran Jing, Alexandra F. Corbin, Kenny Zhi Ming Chen, Yang Tang, Olivia Stockard, Song Yang, Yi Zhou, George Q. Daley, Thorsten M. Schlaeger, Leonard I. Zon

Blood (2023) 142 (Supplement 1): 4071.

https://doi.org/10.1182/blood-2023-180300

Published: 2023

Journal Articles

Prevalence of Ocular Comorbidities in Elderly Patients with Multiple Myeloma in the US: An Analysis of 100% Medicare Sample Data during 2007-2020

Sikander Ailawadhi, Qiufei Ma, Jessica J. Jalbert, Mo Zhou, Zheng-Yi Zhou, Nathaniel Downes, Adina Zhang, Lei Chi, Christian Hampp, Xue Song, Irene Noguera-Troise, Jonathan Weyne, Glenn S. Kroog, Karen Rodriguez Lorenc

Blood (2022) 140 (Supplement 1): 5272–5273.

https://doi.org/10.1182/blood-2022-158401

Published: 2022

Journal Articles

Treatment Patterns and Economic Burden Among Elderly Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A SEER-Medicare Analysis

Andrew M. Brunner, David Huggar, Ronda Copher, Zheng-Yi Zhou, Miriam L. Zichlin, Annika Anderson, Nathaniel Downes, Ali McBride

Blood (2021) 138 (Supplement 1): 4975.

https://doi.org/10.1182/blood-2021-145593

Published: 2021

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A phase 2 trial of abbreviated fixed-duration (Default 4 Cycles) linvoseltamab immuno-consolidation to deepen responses post newly diagnosed multiple myeloma combination therapy for minimal residual disease positivity (the IMMUNOPLANT Study)

A Phase 2 trial of AI-BEL (AZT/Interferon-α plus Belinostat) for HTLV-1 related adult T-cell leukemia-lymphoma: Final safety and efficacy Results

First-in-class small molecule calmodulin pathway modulators attenuate excess p53 activity and correct erythropoietic defects in models of diamond-blackfan anemia (DBA)

Ponatinib alleviates CAR-T cell exhaustion and remodels the immune microenvironment: A promising combination strategy for relapsed/refractory b-ALL

Individualized treatment risk stratification using histopathology-based genomics prediction in multiple myeloma: A multicenter Study in 1429 participants

Clinical translation of single cell measurable residual disease (scMRD) assay in real world Acute Myeloid Leukemia (AML) patients

A cyno cross reactive CD3 VHH antibody enables engineering of a potent CD20-targeted t cell engager with enhanced safety

Targeting of the CD161 Inhibitory Receptor Enhances Bone Marrow-Resident Memory CD8 + T Cell-Mediated Immunity Against Multiple Myeloma

Selinexor, Venetoclax, and Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (SELVEDge Study)

Reducing Time Toxicity for Anti-B-Cell Maturation Antigen (BCMA) Bispecific Treatment: Evidence from Pivotal Single-Arm Trial Data on Teclistamab, Elranatamab, and Linvoseltamab for Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)

Clinical Application of Single-Cell MRD By Genotype and Phenotype in AML

Transcription Factor Programming of Human iPSC-Derived Sinusoidal Vascular Endothelial Cells Enhances Co-Cultured Hematopoietic Stem and Progenitor Cell Transplantation

Safety and Efficacy of AZT-Interferon-α with Belinostat (AI-BEL) for HTLV-1 Related Adult T-Cell Leukemia-Lymphoma

Characterization of Linvoseltamab's BCMA Binding Epitope and Efficacy Against BCMA Mutations in Relapsed/Refractory Multiple Myeloma

Updated Results from a Matching-Adjusted Indirect Comparison of Efficacy Outcomes of Isatuximab Plus Carfilzomib and Dexamethasone Versus Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma

Does Detection of <20% Lymphoblasts in Patients with CML Herald Imminent Blast Crisis? a Study from BCR::ABL1 Pathology Group

Selinexor, Venetoclax, and Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (SELVEDge Study)

In Vivo Reprogramming of Adult Liver Sinusoidal Vascular Endothelial Cells into a Hematopoietic Stem and Progenitor Cell Niche

Prevalence of Ocular Comorbidities in Elderly Patients with Multiple Myeloma in the US: An Analysis of 100% Medicare Sample Data during 2007-2020

Treatment Patterns and Economic Burden Among Elderly Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A SEER-Medicare Analysis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only